New debacle in research for Alzheimer’s therapy: Takeda interrupts Phase III study

The research for an Alzheimer’s treatment has suffered a new defeat. Takeda and its partner Zinfadel Pharmaceuticals have announced they have interrupted the Phase III Tomorrow clinical trial, assessing Actos
(pioglitazone 0.8 mg) in 3,500 patients with Alzheimer’s disease. The trial started in 2016 and has been interrupted as it had failed in delivering the expected results. However, Takeda has stated it plans to keep operating in Alzheimer’s research, indeed it has recently entered into a $1bn agreement with Denali to develop a treatment with a genetic approach.
(Source: Takeda)